ClinicalTrials.gg
CompletedNCT01583036Updated Jun 19, 2018

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

A Phase 1 interventional study of Digoxin Alone and Digoxin + Retigabine in Epilepsy, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-19.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing ezogabine in Epilepsy — none open to participants now, none under way, none of them phase 3. ezogabine · Epilepsy.

Enrollment
8th of 18
30 · median 23
Started
2012
with 5 others
Phase 1
3 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
15 of 18
GlaxoSmithKline

Among the 18 studies testing ezogabine in Epilepsy, this one is the 8th largest by enrollment, is one of 6 that started in 2012, is one of 3 in phase 1, and was the 10th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 18 studies testing ezogabine in Epilepsy is open now. The open studies under Epilepsy, anywhere →

About ezogabine

ezogabine: first FDA approval 2011 (POTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing ezogabine in Epilepsy as a file.
02

Study summary

An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers

Read the detailed description

This is an open-label, single-centre study to evaluate the pharmacokinetics of single-dose digoxin alone and when administered at various up titration doses of ezogabine/retigabine in healthy adult subjects. The pharmacokinetics of ezogabine/retigabine and the n-acetyl metabolite of ezogabine/retigabine (NAMR) will also be assessed.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 65 years of age inclusive, at the time of signing the .
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • A female subject is eligible to participate if she is of: Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and estradiol less than 40 pg/ml (less than 147 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the methods in the protocol if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks should elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 1 week post-last dose of ezogabine/retigabine.
  • Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until at least 1 week post-last dose.
  • of 18 to 30 kg/m2 and total body weight greater than 50 kg (110 lbs).
  • Normal assessed by the Cockcroft-Gault Method.
  • Subject's , ALT, alkaline phosphatase, and are greater than and equal to 1.5 × (isolated bilirubin greater than 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
  • Subject is a nonsmoker (defined as a nonsmoker during the last 3 months prior to Screening and have a negative cotinine test at screening).
  • Subject has a negative drug screen (amphetamines, barbiturates, cocaine metabolites, opiates, benzodiazepines, and cannabinoids) at Screening and at check-in at Day -1.
  • Subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

Exclusion Criteria:

  • Subject has positive test results for surface antigen, positive virus, or (HIV)-1 or -2 at Screening
  • Has active suicidal plan/intent or has had active suicidal thoughts in the past 6 months. Has history of suicide attempt in the last 2 years or more than 1 lifetime suicide attempt.
  • Presence of proteinuria (at least ++) or hematuria or other findings in urinalysis at screening.
  • Has a history of urinary retention or risk factors for urinary retention that in the Investigator's judgment could potentially affect subject safety.
  • Subject has a history of syncope, clinically significant palpitations, bradyarrhythmia or tachyarrhythmia conduction abnormality (e.g., atrioventricular block of any degree, e.g., left bundle-branch block, right bundle-branch block), or Wolf-ParkinsonWhite syndrome, or any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, , or immunogenicity test
  • Subject's blood pressure is greater than and equal to 140/90 mm Hg or heart rate is greater than 100 beats/min at Screening; repeat blood pressures should be taken if the subject's blood pressure is greater than and equal to 140/90 mm Hg and if the results are consistently greater than and equal to 140/90 mm Hg, then the subject should be excluded and advised to consult a physician.
  • Subject's is greater than 450 ms (per ECG machine interpretation) at screening; repeat measurement should be taken if the QTc greater than 450 ms and if the results are consistently greater than 450 ms, then the subject should be excluded
  • Female subject is pregnant or breast-feeding
  • Subject has a history of any anaphylactic reaction to any drug or a known to: LANOXIN/digoxin and/or its , or other digoxin-like medications; or Ezogabine/retigabine; History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Subject has a history of significant cardiovascular or pulmonary dysfunction prior to Screening
  • Subject has a fasting triglyceride level greater than 300 mg/dL at Screening
  • Subject has a current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert syndrome or asymptomatic gallstones)
  • Subject has a history of alcohol or substance abuse within the last 2 years
  • Subject has donated blood in the excess of 500 mL within 56 days prior to dosing or intention of donating in the month after completing the study
  • Subject has a history of gastrointestinal surgery which could influence gastric emptying (e.g., gastrectomy, gastric bypass)
  • Subject has a history of inflammatory bowel disease or irritable bowel syndrome
  • Subject has received an drug within 30 days prior to dosing with study medication or 5 half-lives, whichever is longer
  • Subject is unlikely to comply with the study protocol and/or to complete the study or required study procedures or is unlikely or unable to return for follow-up visits
  • Subject has used prescription medications or over-the-counter medications, herbal supplements, or multivitamins within 14 days prior to dosing with any study medication (beginning with the first dose of digoxin) (see Section 9.2 for additional details)
  • Subject has consumed grapefruit juice, cranberry products (such as juice, fruit, or nutritional supplements), or alcohol, caffeine , or xanthine-containing products within 7 days (or 5 elimination half lives whichever is shorter) prior to start the dosing with study medication
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Session 1 digoxin alone, Session 2 retigabine plus digoxin

    Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.

    Drug: Digoxin Alone · Drug: Digoxin + Retigabine

Interventions

  • Single administration of digoxin 0.25mg

  • DrugDigoxin + Retigabine

    Drug pages: Digoxin · Ezogabine

    Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.

06

What researchers measure

Primary outcomes

  1. Area under the curve of digoxin from zero hours to infinity (Session 1 day 1 & Session 2 days 10, 24 and 38)

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120 and 144 hours post dose

  2. CLr (Renal clearance) of digoxin. Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: 0 to 12 hours, 12 to 24 hours, and 24 to 48 hours post dose

  3. CL/F (Apparent clearance following oral dosing) of digoxin/ Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: 0 to 12 hours, 12 to 24 hours, and 24 to 48 hours post dose

Secondary outcomes

  1. Cmax (Maximum observed concentration) of digoxin. Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120 and 144 hours post dose

  2. Tmax (Time of occurrence of Cmax) of digoxin. Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120 and 144 hours post dose

  3. T 1/2 (Terminal phase half-life) of digoxin. Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120 and 144 hours post dose

  4. Area under the curve of digoxin from zero to 48 hours. Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120 and 144 hours post dose

  5. Area under the curve of digoxin from zero to 144 hours. Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120 and 144 hours post dose

  6. Ae (Urinary recovery of unchanged drug) of digoxin from zero to 48 hours. Session 1 day 1 & Session 2 days 10, 24 and 38

    Time frame: 0 to 12 hours, 12 to 24 hours, and 24 to 48 hours post dose

  7. Cmax of NAMR and ezogabine / retigabine. Days 10, 24 and 38

    Time frame: pre dose, 0.25, 0.5 1, 1.5, 2, 3, 4, 6, and 8, hours post dose.

  8. Tmax of NAMR and ezogabine / retigabine. Days 10, 24 and 38

    Time frame: pre dose, 0.25, 0.5 1, 1.5, 2, 3, 4, 6, and 8, hours post dose.

  9. Area under the curve of NAMR and ezogabine / retigabine from zero hours to τ (Time of last observed quantifiable concentration). Days 10, 24 and 38

    Time frame: pre dose, 0.25, 0.5 1, 1.5, 2, 3, 4, 6, and 8, hours post dose.

  10. Safety and Tolerability (AE's, clinical laboratory, vital signs assessments, ECG's and C-SSRs)

    Time frame: Session 1 day 1 to Session 2 follow-up

07

Study locations

1 site
  • GSK Investigational Site
    Baltimore, Maryland 21225, United States
08

References and documents

Publications

  • Crean C, Tompson D, Buraglio M. Effects of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy volunteers: results from a drug-drug interaction Phase I study . Epilepsia. 2013;54(Suppl. 3):166.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Apr 2012, 3 months.

Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 3 months is below that.

Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2012
First posted
Apr 23, 2012
StartActual
Jan 16, 2012
Primary completionActual
Apr 17, 2012
CompletionActual
Apr 17, 2012
Last update
Jun 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01583036
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 23, 2012
Start date
Jan 16, 2012
Primary completion
Apr 17, 2012
Completion
Apr 17, 2012
Last update
Jun 19, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · Ezogabine

Start the discussion